AI Verdict
NXTC has stronger fundamentals based on our AI analysis.
NYC vs NXTC Fundamental Comparison
| Metric | NYC | NXTC |
|---|---|---|
| Revenue | $0.0 | $22.4M |
| Net Income | $-14.5M | $-55.8M |
| Net Margin | N/A | -249.5% |
| ROE | -20.3% | -159.8% |
| ROA | -3.2% | -111.3% |
| Current Ratio | N/A | 4.14x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $-5.70 | $-19.65 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
NYC vs NXTC: Frequently Asked Questions
Is NYC or NXTC a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), NXTC has stronger fundamentals. NYC is rated STRONG SELL (95% confidence) while NXTC is rated SELL (78% confidence). This is not investment advice.
How does NYC compare to NXTC fundamentally?
American Strategic Investment Co. has ROE of -20.3% vs NextCure, Inc.'s -159.8%. Net margins are N/A vs -249.5% respectively.
Which stock pays higher dividends, NYC or NXTC?
NYC has a dividend yield of N/A or no dividend while NXTC has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in NYC or NXTC for long term?
For long-term investing, consider that NYC has STRONG SELL rating with 95% confidence, while NXTC has SELL rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about NYC vs NXTC?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For NYC vs NXTC, the AI consensus favors NXTC based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.